Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream

References

• SiegelRLMillerKDJemalACancer statisticsCA: Cancer J Clin201868173029313949
   PubMed Web of Science ®Google Scholar
• LenzHJNiedzwieckiDInnocentiFCALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (MFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients with expanded RAS analyses untreated metastatic adenocarcinoma of the colon or rectum (mCRC)Paper presented at: ESMO CongressMadrid, Spain2014
   Google Scholar
• HeinemannVvon WeikersthalLFDeckerTFOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialLancet Oncol201415101065107525088940
   PubMed Web of Science ®Google Scholar
• SchwartzbergLSRiveraFKarthausMPEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancerJ Clin Oncol201432212240224724687833
   PubMed Web of Science ®Google Scholar
• GoelGChauhanAHoseinPJRamucirumab: a novel anti-angiogenic agent in the treatment of metastatic colorectal cancerCurr Colorectal Cancer Rep2016125232240
   Google Scholar
• GoelGEvolution of regorafenib from bench to bedside in colorectal cancer: is it an attractive option or merely a “me too” drug?Cancer Manag Res20181042543729563833
   PubMed Web of Science ®Google Scholar
• FearonERVogelsteinBA genetic model for colorectal tumorigenesisCell19906157597672188735
   PubMed Web of Science ®Google Scholar
• ShihIMZhouWGoodmanSNLengauerCKinzlerKWVogelsteinBEvidence that genetic instability occurs at an early stage of colorectal tumorigenesisCancer Res200161381882211221861
   PubMed Web of Science ®Google Scholar
• GuinneyJDienstmannRWangXThe consensus molecular subtypes of colorectal cancerNat Med201521111350135626457759
   PubMed Web of Science ®Google Scholar
• KarnoubAEWeinbergRARas oncogenes: split personalitiesNat Rev Mol Cell Biol20089751753118568040
   PubMed Web of Science ®Google Scholar
• WongRCunninghamDUsing predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodiesJ Clin Oncol200826355668567019001346
   PubMed Web of Science ®Google Scholar
• LièvreABachetJBLe CorreDKRAS mutation status is predictive of response to cetuximab therapy in colorectal cancerCancer Res20066683992399516618717
   PubMed Web of Science ®Google Scholar
• KarapetisCSKhambata-FordSJonkerDJK-ras mutations and benefit from cetuximab in advanced colorectal cancerN Engl J Med2008359171757176518946061
   PubMed Web of Science ®Google Scholar
• AmadoRGWolfMPeetersMWild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerJ Clin Oncol200826101626163418316791
   PubMed Web of Science ®Google Scholar
• van CutsemEKöhneC-HHitreECetuximab and chemotherapy as initial treatment for metastatic colorectal cancerN Engl J Med Overseas Ed20093601414081417
   PubMed Web of Science ®Google Scholar
• BokemeyerCBondarenkoIMakhsonAFluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancerJ Clin Oncol200927566367119114683
   PubMed Web of Science ®Google Scholar
• DouillardJYSienaSCassidyJRandomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME studyJ Clin Oncol201028314697470520921465
   PubMed Web of Science ®Google Scholar
• PeetersMPriceTJCervantesARandomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancerJ Clin Oncol201028314706471320921462
   PubMed Web of Science ®Google Scholar
• AdelsteinB-ADobbinsTAHarrisCAMarschnerICWardRLA systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancerEur J Cancer20114791343135421550229
   PubMed Web of Science ®Google Scholar
• DahabrehIJTerasawaTCastaldiPJTrikalinosTASystematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancerAnn Intern Med20111541374921200037
   PubMed Web of Science ®Google Scholar
• LoupakisFCremoliniCSalvatoreLClinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategiesCancer201211861523153222009364
   PubMed Web of Science ®Google Scholar
• ValeCLTierneyJFFisherDDoes anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysisCancer Treat Rev201238661862522118887
   PubMed Web of Science ®Google Scholar
• DouillardJ-YOlinerKSSienaSPanitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancerN Engl J Med Overseas Ed20133691110231034
   PubMed Web of Science ®Google Scholar
• SorichMJWieseMDRowlandAKichenadasseGMckinnonRAKarapetisCSExtended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trialsAnn Oncol2015261132125115304
   PubMed Web of Science ®Google Scholar
• van CutsemELenzHJKöhneCHFluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancerJ Clin Oncol201533769270025605843
   PubMed Web of Science ®Google Scholar
• SepulvedaARHamiltonSRAllegraCJMolecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical OncologyJ Clin Oncol201735131453148628165299
   PubMed Web of Science ®Google Scholar
• AndreyevHJNormanARCunninghamDKirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ studyBr J Cancer200185569269611531254
   PubMed Web of Science ®Google Scholar
• RichmanSDSeymourMTChambersPKRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trialJ Clin Oncol200927355931593719884549
   PubMed Web of Science ®Google Scholar
• KimSTParkKHKimJSShinSWKimYHImpact of KRAS mutation status on outcomes in metastatic colon cancer patients without anti-epidermal growth factor receptor therapyCancer Res Treat2013451556223613671
   PubMed Web of Science ®Google Scholar
• RenJLiGGeJLiXZhaoYIs K-ras gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysisDis Colon Rectum201255891392322810479
   PubMed Web of Science ®Google Scholar
• de RoockWClaesBBernasconiDEffects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisLancet Oncol201011875376220619739
   PubMed Web of Science ®Google Scholar
• di NicolantonioFMartiniMMolinariFWild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancerJ Clin Oncol200826355705571219001320
   PubMed Web of Science ®Google Scholar
• TolJDijkstraJRKlompMMarkers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximabEur J Cancer201046111997200920413299
   PubMed Web of Science ®Google Scholar
• van CutsemEKöhneCHLángICetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation statusJ Clin Oncol201129152011201921502544
   PubMed Web of Science ®Google Scholar
• BokemeyerCvan CutsemERougierPAddition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trialsEur J Cancer201248101466147522446022
   PubMed Web of Science ®Google Scholar
• LinJSWebberEMSengerCAHolmesRSWhitlockEPSystematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancerAm J Cancer Res20111565066221779535
   PubMed Web of Science ®Google Scholar
• XuQXuATZhuMMTongJLXuXTRanZHPredictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysisJ Dig Dis201314840941623615046
   PubMed Web of Science ®Google Scholar
• YuanZXWangXYQinQYThe prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysisPLoS One201386e6599523776587
   PubMed Web of Science ®Google Scholar
• YangZYWuXYHuangYFPromising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysisInt J Cancer201313381914192523494461
   PubMed Web of Science ®Google Scholar
• RowlandADiasMMWieseMDMeta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancerBr J Cancer2015112121888189425989278
   PubMed Web of Science ®Google Scholar
• PietrantonioFPetrelliFCoinuAPredictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysisEur J Cancer201551558759425673558
   PubMed Web of Science ®Google Scholar
• SeymourMTBrownSRMiddletonGPanitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trialLancet Oncol201314874975923725851
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas NetworkComprehensive molecular characterization of human colon and rectal cancerNature2012487740733033722810696
   PubMed Web of Science ®Google Scholar
• AaltonenLASalovaaraRKristoPIncidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the diseaseN Engl J Med Overseas Ed19983382114811487
   PubMed Web of Science ®Google Scholar
• Evaluation of Genomic Applications in Prevention Working GroupRecommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relativesGenet Med2009111354119125126
   PubMed Web of Science ®Google Scholar
• HampelHFrankelWLMartinEFeasibility of screening for Lynch syndrome among patients with colorectal cancerJ Clin Oncol200826355783578818809606
   PubMed Web of Science ®Google Scholar
• SinicropeFAFosterNRThibodeauSNDNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapyJ Natl Cancer Inst20111031186387521597022
   PubMedGoogle Scholar
• LanzaGGafàRMaestriISantiniAMatteuzziMCavazziniLImmunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instabilityMod Pathol200215774174912118112
   PubMed Web of Science ®Google Scholar
• PopatSHubnerRHoulstonRSSystematic review of microsatellite instability and colorectal cancer prognosisJ Clin Oncol200523360961815659508
   PubMed Web of Science ®Google Scholar
• MyintZWGoelGRole of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progressJ Hematol Oncol20171018628434400
   PubMedGoogle Scholar
• SargentDJMarsoniSMongesGDefective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancerJ Clin Oncol201028203219322620498393
   PubMed Web of Science ®Google Scholar
• LipsonEJSharfmanWHDrakeCGDurable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibodyClin Cancer Res201319246246823169436
   PubMed Web of Science ®Google Scholar
• LlosaNJCruiseMTamAThe vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpointsCancer Discov201551435125358689
   PubMed Web of Science ®Google Scholar
• DtLUramJNWangHPD-1 blockade in tumors with mismatch-repair deficiencyN Engl J Med2015372262509252026028255
   PubMed Web of Science ®Google Scholar
• DtLUramJNWangHProgrammed death-1 blockade in mismatch repair deficient colorectal cancerJ Clin Oncol20163410326628472
   PubMed Web of Science ®Google Scholar
• OvermanMJMcdermottRLeachJLNivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 studyLancet Oncol20171891182119128734759
   PubMed Web of Science ®Google Scholar
• OvermanMJLonardiSWongKYMDurable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancerJ Clin Oncol201836877377929355075
   PubMed Web of Science ®Google Scholar
• GongJWangCLeePPChuPFakihMResponse to PD-1 blockade in microsatellite stable metastatic colorectal cancer harboring a POLE mutationJ Natl Compr Cancer Netw2017152142147
   PubMed Web of Science ®Google Scholar
• GrayRGQuirkePHandleyKValidation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancerJ Clin Oncol201129354611461922067390
   PubMed Web of Science ®Google Scholar
• VenookAPNiedzwieckiDLopatinMBiologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581J Clin Oncol201331141775178123530100
   PubMed Web of Science ®Google Scholar
• SalazarRRoepmanPCapellaGGene expression signature to improve prognosis prediction of stage II and III colorectal cancerJ Clin Oncol2011291172421098318
   PubMed Web of Science ®Google Scholar
• GoelGEvolving role of gene expression signatures as bio-markers in early-stage colon cancerJ Gastrointest Cancer201445439940424989938
   PubMedGoogle Scholar
• VelhoSOliveiraCFerreiraAThe prevalence of PIK3CA mutations in gastric and colon cancerEur J Cancer200541111649165415994075
   PubMed Web of Science ®Google Scholar
• BaraultLVeyrieNJoosteVMutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancersInt J Cancer2008122102255225918224685
   PubMed Web of Science ®Google Scholar
• MaoCYangZYHuXFChenQTangJLPIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysisAnn Oncol20122361518152522039088
   PubMed Web of Science ®Google Scholar
• WuSGanYWangXLiuJLiMTangYPIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysisJ Cancer Res Clin Oncol2013139589190023435830
   PubMed Web of Science ®Google Scholar
• ColakogluTYildirimSKayaselcukFClinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence?Am J Surg2008195671972518440486
   PubMed Web of Science ®Google Scholar
• SawaiHYasudaAOchiNLoss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survivalBMC Gastroenterol2008815619036165
   PubMedGoogle Scholar
• XhLZhengHCTakahashiHMasudaSYangXHTakanoYPTEN expression and mutation in colorectal carcinomasOncol Rep200922475776419724853
   PubMed Web of Science ®Google Scholar
• LinMSHuangJXChenWCExpression of PPARγ and PTEN in human colorectal cancer: an immunohistochemical study using tissue microarray methodologyOncol Lett2011261219122422848291
   PubMed Web of Science ®Google Scholar
• PriceTJHardinghamJELeeCKPrognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumabCancer Med20132327728523930204
   PubMed Web of Science ®Google Scholar
• EklöfVWikbergMLEdinSThe prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancerBr J Cancer2013108102153216323660947
   PubMed Web of Science ®Google Scholar
• FrattiniMSalettiPRomagnaniEPTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patientsBr J Cancer20079781139114517940504
   PubMed Web of Science ®Google Scholar
• PerroneFLampisAOrsenigoMPI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patientsAnn Oncol2009201849018669866
   PubMed Web of Science ®Google Scholar
• LoupakisFPollinaLStasiIPTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancerJ Clin Oncol200927162622262919398573
   PubMed Web of Science ®Google Scholar
• NegriFVBozzettiCLagrastaCAPTEN status in advanced colorectal cancer treated with cetuximabBr J Cancer2010102116216419953097
   PubMed Web of Science ®Google Scholar
• Laurent-PuigPCayreAManceauGAnalysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancerJ Clin Oncol200927355924593019884556
   PubMed Web of Science ®Google Scholar
• UliviPCapelliLValgiustiMPredictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center studyJ Transl Med20121018722569004
   PubMedGoogle Scholar
• KarapetisCSJonkerDDaneshmandMPIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer—results from NCIC CTG/AGITG CO.17Clin Cancer Res201420374475324218517
   PubMed Web of Science ®Google Scholar
• MolinariFFrattiniMFunctions and regulation of the PTEN gene in colorectal cancerFront Oncol2013332624475377
   PubMedGoogle Scholar
• SridharanMHubbardJMGrotheyAColorectal cancer: how emerging molecular understanding affects treatment decisionsOncology201428211011824701697
   PubMed Web of Science ®Google Scholar
• CejasPLopez-GomezMAguayoCAnalysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients: implications for cancer therapyCurr Cancer Drug Targets201212212413122229245
   PubMed Web of Science ®Google Scholar
• ValtortaEMartinoCSartore-BianchiAAssessment of a HER2 scoring system for colorectal cancer: results from a validation studyMod Pathol201528111481149126449765
   PubMed Web of Science ®Google Scholar
• Sartore-BianchiATrusolinoLMartinoCDual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trialLancet Oncol201617673874627108243
   PubMed Web of Science ®Google Scholar
• GalonJCostesASanchez-CaboFType, density, and location of immune cells within human colorectal tumors predict clinical outcomeScience200631357951960196417008531
   PubMed Web of Science ®Google Scholar
• HalamaNMichelSKloorMLocalization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapyCancer Res201171175670567721846824
   PubMed Web of Science ®Google Scholar
• GalonJPagèsFMarincolaFMCancer classification using the Immunoscore: a worldwide task forceJ Transl Med201210120523034130
   PubMed Web of Science ®Google Scholar
• GalonJMlecnikBMarliotFValidation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: results of a worldwide consortium-based analysis of 1,336 patientsJ Clin Oncol201634Suppl abstr 3500
   Google Scholar
• PagèsFMlecnikBMarliotFInternational validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy studyLancet2018391101352128213929754777
   PubMed Web of Science ®Google Scholar
• WerlingRWYazijiHBacchiCEGownAMCDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomasAm J Surg Pathol200327330331012604886
   PubMed Web of Science ®Google Scholar
• BabaYNoshoKShimaKRelationship of CDX2 loss with molecular features and prognosis in colorectal cancerClin Cancer Res200915144665467319584150
   PubMed Web of Science ®Google Scholar
• DalerbaPSahooDPaikSCDX2 as a prognostic biomarker in stage II and stage III colon cancerN Engl J Med Overseas Ed20163743211222
   PubMed Web of Science ®Google Scholar
• LoupakisFYangDYauLPrimary tumor location as a prognostic factor in metastatic colorectal cancerJ Natl Cancer Inst20151073dju42725713148
   PubMedGoogle Scholar
• TejparSStintzingSCiardielloFPrognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trialsJAMA Oncol201632194201
   Web of Science ®Google Scholar
• VenookAPNiedzwieckiDInnocentiFImpact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance)J Clin Oncol201634suppl abstr 3504
   Google Scholar
• BartelDPMicroRNAs: target recognition and regulatory functionsCell2009136221523319167326
   PubMed Web of Science ®Google Scholar
• SchetterAJOkayamaHHarrisCCThe role of microRNAs in colorectal cancerCancer J201218324425222647361
   PubMed Web of Science ®Google Scholar
• LouXQiXZhangYLongHYangJDecreased expression of microRNA-625 is associated with tumor metastasis and poor prognosis in patients with colorectal cancerJ Surg Oncol2013108423023523861214
   PubMed Web of Science ®Google Scholar
• YangI-PTsaiH-LHuangC-WThe functional significance of microRNA-29c in patients with colorectal cancer: a potential circulating biomarker for predicting early relapsePLoS One201386e6684223840538
   PubMed Web of Science ®Google Scholar
• ZhangYUWangXXuBEpigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancerOncol Rep20133041976198423900443
   PubMed Web of Science ®Google Scholar
• DongYZhaoJWuCWCwWTumor suppressor functions of miR-133a in colorectal cancerMol Cancer Res20131191051106023723074
   PubMed Web of Science ®Google Scholar
• KaraayvazMZhaiHJuJmiR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancerCell Death Dis20134e65923744359
   PubMed Web of Science ®Google Scholar
• LiuXPanBSunLCirculating exosomal miR-27a and miR-130a act as novel diagnostic and prognostic biomarkers of colorectal cancerCancer Epidemiol Biomarkers Prev201827774675429739748
   PubMed Web of Science ®Google Scholar
• WangLWheelerDAGenomic sequencing for cancer diagnosis and therapyAnnu Rev Med201465334824274147
   PubMed Web of Science ®Google Scholar
• WangXKuangYYHuXTXtHAdvances in epigenetic biomarker research in colorectal cancerWorld J Gastroenterol201420154276428724764665
   PubMed Web of Science ®Google Scholar
• DeySSKesterLSpanjaardBBienkoMvan OudenaardenAIntegrated genome and transcriptome sequencing of the same cellNat Biotechnol201533328528925599178
   PubMed Web of Science ®Google Scholar
• DienstmannRVermeulenLGuinneyJKopetzSTejparSTaberneroJConsensus molecular subtypes and the evolution of precision medicine in colorectal cancerNat Rev Cancer2017172799228050011
   PubMed Web of Science ®Google Scholar
• van EngelandMDerksSSmitsKMMeijerGAHermanJGColorectal cancer epigenetics: complex simplicityJ Clin Oncol201129101382139121220596
   PubMed Web of Science ®Google Scholar
• ZhangBWangJWangXProteogenomic characterization of human colon and rectal cancerNature2014513751838238725043054
   PubMed Web of Science ®Google Scholar
• UhlenMFagerbergLHallstromBMTissue-based map of the human proteomeScience20153476220126041925613900
   PubMed Web of Science ®Google Scholar
• BettegowdaCSausenMLearyRJDetection of circulating tumor DNA in early- and late-stage human malignanciesSci Transl Med20146224224ra224
   Web of Science ®Google Scholar
• ThierryARMouliereFEl MessaoudiSClinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNANat Med201420443043524658074
   PubMed Web of Science ®Google Scholar
• DiazLAWilliamsRTWuJThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancersNature2012486740453754022722843
   PubMed Web of Science ®Google Scholar
• MisaleSYaegerRHoborSEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerNature2012486740453253622722830
   PubMed Web of Science ®Google Scholar
• NewmanAMBratmanSVToJAn ultrasensitive method for quantitating circulating tumor DNA with broad patient coverageNat Med201420554855424705333
   PubMed Web of Science ®Google Scholar
• DiazLABardelliALiquid biopsies: genotyping circulating tumor DNAJ Clin Oncol201432657958624449238
   PubMed Web of Science ®Google Scholar
• SausenMParpartSDiazLACirculating tumor DNA moves further into the spotlightGenome Med2014653524944584
   PubMedGoogle Scholar
• CohenSJPuntCJIannottiNRelationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancerJ Clin Oncol200826193213322118591556
   PubMed Web of Science ®Google Scholar
• RomitiARaffaSdi RoccoRCirculating tumor cells count predicts survival in colorectal cancer patientsJ Gastrointestin Liver Dis201423327928425267956
   PubMed Web of Science ®Google Scholar
• HuangXGaoPSongYRelationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysisBMC Cancer20141497625519477
   PubMed Web of Science ®Google Scholar
• KopetzSDesaiJChanEPLX4032 in metastatic colorectal cancer patients with mutant BRAF tumorsJ Clin Oncol20102815_Suppl3534
   Google Scholar
• PrahalladASunCHuangSUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFRNature2012483738710010322281684
   PubMed Web of Science ®Google Scholar
• CorcoranRBEbiHTurkeABEGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenibCancer Discov20122322723522448344
   PubMed Web of Science ®Google Scholar
• Triple therapy improves colorectal cancer responseCancer Discov2016612OF6
   Google Scholar
• GerlingerMRowanAJHorswellSIntratumor heterogeneity and branched evolution revealed by multiregion sequencingN Engl J Med20123661088389222397650
   PubMed Web of Science ®Google Scholar
• BedardPLHansenARRatainMJSiuLLTumour heterogeneity in the clinicNature2013501746735536424048068
   PubMed Web of Science ®Google Scholar
• VogelsteinBPapadopoulosNVelculescuVEZhouSDiazLAKinzlerKWCancer genome landscapesScience201333961271546155823539594
   PubMed Web of Science ®Google Scholar
• PuntCJKoopmanMVermeulenLFrom tumour heterogeneity to advances in precision treatment of colorectal cancerNat Rev Clin Oncol201714423524627922044
   PubMed Web of Science ®Google Scholar
• ArenaSBellosilloBSiravegnaGEmergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancerClin Cancer Res20152192157216625623215
   PubMed Web of Science ®Google Scholar
• BurrellRAMcgranahanNBartekJSwantonCThe causes and consequences of genetic heterogeneity in cancer evolutionNature2013501746733834524048066
   PubMed Web of Science ®Google Scholar
• MeachamCEMorrisonSJTumour heterogeneity and cancer cell plasticityNature2013501746732833724048065
   PubMed Web of Science ®Google Scholar
• BendellJCKimTWGohBCClinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC)J Clin Oncol201634Supplabstr 3502
   Google Scholar